Drugs / Quavonlimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials · 1 missed | ||||||
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03179436 | Jul 2017 → Apr 2024 | cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04740307 | Mar 2021 → Jul 2025 | hepatocellular carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT03516981 | Oct 2018 → Jun 2025 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Merck Sharp & Dohme LLC | Results Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) merck.com ↗
At a pre-specified interim analysis, the combination regimens did not meet the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for the first-line treatment of patients with RCC compared to KEYTRUDA plus LENVIMA. |
| 2020-10-16 | Merck Sharp & Dohme LLC | Results Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer merck.com ↗
Additionally, updated follow-up data from a Phase 1/2 study of quavonlimab in combination with KEYTRUDA showed encouraging anti-tumor activity and an acceptable safety profile as first-line treatment in patients with advanced NSCLC (Poster #TS01.02). |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516981 ↗ |
| Known as | MK-1308 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650419 ↗ |
| Known as | QUAVONLIMAB COMPONENT OF MK-1308A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650419 ↗ |
| Action | Inhibit | “anti-CTLA-4 quavonlimab” PMID 37429923 ↗ Jul 2023 |
| Modality | Monoclonal antibody | “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab” PMID 34371366 ↗ Jul 2021 |
| Route | Intravenous | “Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy...” NCT03179436 ↗ |
| Target | CTLA4 | “anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab” PMID 34371366 ↗ Jul 2021 |